Back to top

Names Under Consideration

Back to top

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more. 

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

June, 2017

levafoxolaner: insecticide for killing fleas and ticks in dogs 

May, 2017

cirotregcel: treatment of auto-immune disorders, specifically type 1 Diabetes

dilancorcel: reconstitution of the hematopoietic system to fight chemotherapy induced neutropenia

edatristat: treatment of pulmonary arterial hypertension

ledacorcel: reconstitution of the hematopoietic system to fight chemotherapy induced neutropenia

rodatristat: treatment of pulmonary arterial hypertension

temastermin: locally administered agent to increase muscle mass and strength in specific muscles, for the treatment of focal myopathies

April, 2017

mipretinib: treatment of cancer

ripretinib: treatment of cancer

turzepatide: treatment of type 2 diabetes

vanotagrin mesylate: treatment of cognition disorders; treatment of Alzheimer’s disease

Print this page Email this page